

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

March 2010

Vol. 38, No. 3

CONTENTS

SHORT COMMUNICATION

- Down-Regulation of Liver Drug-Metabolizing Enzymes in a Murine Model of Chronic Renal Failure. *Mélina Dani, Caroline Boisvert, Josée Michaud, Judith Naud, Stéphane Lefrançois, Francois A. Leblond, and Vincent Pichette* **357**

ARTICLES

- Identification of a Novel *N*-Carbamoyl Glucuronide: In Vitro, In Vivo, and Mechanistic Studies. *Mithat Gunduz, Upendra A. Argikar, Daniel Baeschlin, Suzie Ferreira, Vinayak Hosagrahara, and Shawn Harriman* **361**

- Identification of Human UGT2B7 as the Major Isoform Involved in the *O*-Glucuronidation of Chloramphenicol. *Mei Chen, Barbara LeDuc, Stephen Kerr, David Howe, and David A. Williams* **368**

- Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator. *Jakob Jornil, Klaus Gjervig Jensen, Frank Larsen, and Kristian Linnet* **376**

- Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases. *Nenad Manevski, Mika Kurkela, Camilla Höglund, Timo Mauriala, Michael H. Court, Jari Yli-Kaahuoma, and Moshe Finel* **386**

- S** Current Cytochrome P450 Phenotyping Methods Applied to Metabolic Drug-Drug Interaction Prediction in Dogs. *Beth Miskimins Mills, Matthew J. Zaya, Rodney R. Walters, Kenneth L. Feenstra,*

- Julie A. White, Jason Gagne, and Charles W. Locuson* **396**

- S** In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans. *M. Obermeier, M. Yao, A. Khanna, B. Koplowitz, M. Zhu, W. Li, B. Komoroski, S. Kasichayanula, L. Discenza, W. Washburn, W. Meng, B. A. Ellsworth, J. M. Whaley, and W. G. Humphreys* **405**

- New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4. *Jessica Mwynyi, Jana Nekvindová, Isa Cavaco, Yvonne Hofmann, Rasmus Steen Pedersen, Ellie Landman, Souren Mkrtchian, and Magnus Ingelman-Sundberg* **415**

- In Silico Prediction of Biliary Excretion of Drugs in Rats Based on Physicochemical Properties. *Gang Luo, Stephen Johnson, Mei-Mann Hsueh, Joanna Zheng, Hong Cai, Baomin Xin, Saeho Chong, Kan He, and Timothy W. Harper* **422**

- Glucuronidation of Dihydrotestosterone and *trans*-Androsterone by Recombinant UDP-Glucuronosyltransferase (UGT) 1A4: Evidence for Multiple UGT1A4 Aglycone Binding Sites. *Jin Zhou, Timothy S. Tracy, and Rory P. Remmel* **431**

- Monocarboxylate Transporter-Mediated Transport of γ -Hydroxybutyric Acid in Human Intestinal Caco-2 Cells. *Wing Ki Lam, Melanie A. Felmlee, and Marilyn E. Morris* **441**

- In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induc-

Continued on next page

tion Studies. <i>Lifei Wang, Donglu Zhang, Nirmala Raghavan, Ming Yao, Li Ma, Charles A. Frost, Brad D. Maxwell, Shiang-yuan Chen, Kan He, Theunis C. Goosen, W. Griffith Humphreys, and Scott J. Grossman</i>	448	<i>Owen, Ismael J. Hidalgo, Jibin Li, Wei Zhang, and Tommy B. Andersson</i>	491
Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys. <i>Eugene Y. Tan, Georgy Hartmann, Qing Chen, Antonio Pereira, Scott Bradley, George Doss, Andy Shiqiang Zhang, Jonathan Z. Ho, Matthew P. Braun, Dennis C. Dean, Wei Tang, and Sanjeev Kumar</i>	459	☐ Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans. <i>Yongchuan Gu, Graham J. Atwell, and William R. Wilson</i>	498
Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans. <i>Sanjeev Kumar, Eugene Y. Tan, Georgy Hartmann, Zachary Biddle, Arthur J. Bergman, James Dru, Jonathan Z. Ho, Allen N. Jones, Steve J. Staskiewicz, Matthew P. Braun, Bindhu Karanam, Dennis C. Dean, Isaias Noel Gendrano, Mark W. Graves, John A. Wagner, and Rajesh Krishna</i>	474	Glucuronide Production by Whole-Cell Biotransformation Using Genetically Engineered Fission Yeast <i>Schizosaccharomyces pombe</i> . <i>Călin-Aurel Drăgan, Daniela Buchheit, Daniel Bischoff, Thomas Ebner, and Matthias Bureik</i>	509
UDP-Glucuronosyltransferase 1A10: Activity against the Tobacco-Specific Nitrosamine, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a Potential Role for a Novel UGT1A10 Promoter Deletion Polymorphism in Cancer Susceptibility. <i>Rene M. Balliet, Gang Chen, Ryan W. Dellinger, and Philip Lazarus</i>	484	☐ Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells. <i>Sébastien Anthérieu, Christophe Chesné, Ruoya Li, Sandrine Camus, Agustin Lahoz, Laura Picazo, Miia Turpeinen, Ari Tolonen, Jouko Uusitalo, Christiane Guguen-Guillouzo, and André Guillouzo</i>	516
Investigation of the Involvement of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 in the Efflux of Ximelagatran and Its Metabolites by Using Short Hairpin RNA Knockdown in Caco-2 Cells. <i>Malin Darnell, Johan E. Karlsson, Albert</i>		☐ Expressions of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Genes in Monolayer Carcinoma Cells Change in Subcutaneous Tumors Grown As Xenografts in Immunodeficient Nude Mice. <i>Michiko Sugawara, Kiyoshi Okamoto, Tadashi Kadowaki, Kazutomi Kusano, Akiyoshi Fukamizu, and Tsutomu Yoshimura</i>	526
		LETTERS TO THE EDITOR	
		Comment on “Permeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Study”. <i>Yuan-Sheng Zhao, Zhe-Yi Hu, Rong-Rong Jiang, Jun-Ling Yang, and Feng Chen</i>	534
		Response to Letter to the Editor on “Permeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Study”. <i>Huadong Sun and K. Sandy Pang</i>	536

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: The HepaRG cells were incubated with fluorescent substrates (CDFDA, fluorescent substrate of MRP2 and BODIPY FL vinblastine, fluorescent substrate of BSEP and MDRI) for 30 min at 37°C and then observed under phase contrast and fluorescence microscopy. See the article by Anthérieu et al. on page 516 of this issue.